Natera的争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 6 条
2021
Natera就涉嫌专利侵权起诉Inivata
提起诉讼
在一起诉讼中，Natera对Inivata Ltd.及其全资子公司提出指控，称其侵犯两项美国专利。Natera寻求禁令救济和金钱赔偿。这些内容属于诉讼中提出的指控，并非已陈述的法院裁定。该诉讼涉及所称的专利侵权以及Natera寻求的救济。
Natera起诉Inivata Ltd.及其全资子公司，指控其侵犯两项美国专利。Natera要求禁令救济和金钱赔偿；这些内容属于诉讼指控，并非已陈述的法院裁定。
来源摘录
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, filed a lawsuit today against Inivata, Ltd. and its wholly-owned subsidiary Inivata, Inc. for alleged infringement of Natera's U.S. Patent Nos. 10,262,755 and 10,597,709.
Natera is seeking both injunctive relief and monetary damages.
2021
Guardant Health就涉嫌误导性广告起诉Natera
提起诉讼
Guardant Health起诉Natera，指称其针对Guardant的Reveal癌症检测产品开展虚假和误导性广告宣传，并与自家产品作出缺乏科学依据的比较。此为诉讼中的指控。
来源摘录
Guardant Health Inc., an oncology company based in Delaware, sued Natera, Inc. on Thursday over allegations that Natera has led a “campaign of false and misleading advertising,” in regard to Guardant’s product, called the Guardant Reveal liquid biopsy cancer assay (Reveal) for early-stage colorectal cancer (CRC).
The defendants are said to have misrepresented Reveal, as they describe their product Signatera as one that is superior in sensitivity, failure rate, negative predictive value, and Hazard Ratio.
2020
Natera 起诉 CareDx 专利侵权
提起诉讼
Natera 宣布已对 CareDx 提起诉讼，指控其侵犯 Natera 的美国专利 10,526,658。该公告呈现的是 Natera 的指控，并未称法院已就此作出裁定。来源将该诉讼描述为 Natera 对 CareDx 提起的专利侵权诉讼。
来源摘录
today filed suit against CareDx for infringing its U.S. Patent 10,526,658 ("the '658 patent").
2020
Natera 起诉 Progenity 专利侵权
提起诉讼
Natera 在美国德克萨斯州西区联邦地区法院起诉 Progenity，指称 Progenity 使用和销售非侵入性产前检测产品侵犯六项专利。Natera 请求禁令救济及金钱赔偿。来源报道的是指控，并未报告法院裁定。
来源摘录
filed suit today against Progenity, Inc. for infringing six patents: U.S. Patents 9,228,234; 9,424,392; 10,227,652; 10,240,202; 10,266,893; and 10,522,242 (the "Asserted Patents").
The suit was filed in the U.S. District Court for the Western District of Texas, and alleges that the use and sale of Progenity's non-invasive prenatal test infringe the six Asserted Patents.
2020
Natera 起诉 ArcherDX 专利侵权
提起诉讼
Natera 在美国特拉华州联邦地区法院起诉 ArcherDX。Natera 的诉状指称 ArcherDX 销售和使用某些基于游离 DNA 的肿瘤产品侵犯其专利；报道未称法院已作出认定。
来源摘录
Natera, Inc. (NASDAQ: NTRA) a global leader in cell-free DNA testing, filed suit today against ArcherDX for infringement of Natera's U.S. Patent No. 10,538,814 (the "'814 patent").
2018